Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Goserelin Acetate

FDA-approved product (implant, implantation), marketed as Zoladex.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Goserelin Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Carcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Gonadotropin releasing hormone analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli58.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Goserelin Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Goserelin Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)

    NCT05063786 · start 2021-09-14

    Registered record
    Registry ID
    NCT05063786
    Conditions
    Advanced Breast Cancer
    Interventions
    Trastuzumab; Alpelisib; Fulvestrant; Vinorelbine; Capecitabine; Eribulin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-09-14
    Completion
    2026-06
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Cancer
    InterventionTrastuzumab; Alpelisib; Fulvestrant; Vinorelbine +2 more
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

    NCT04961996 · start 2021-08-27

    Registered record
    Registry ID
    NCT04961996
    Conditions
    Early Breast Cancer
    Interventions
    Giredestrant; Physician's Choice of Endocrine Therapy; LHRH Agonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-08-27
    Completion
    2033-09-30
    Enrolment
    4,170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEarly Breast Cancer
    InterventionGiredestrant; Physician's Choice of Endocrine Therapy; LHRH Agonist
    PhasePhase 3
    Registry statusActive not recruiting

  • Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

    NCT04513717 · start 2021-01-21

    Registered record
    Registry ID
    NCT04513717
    Conditions
    Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
    Interventions
    Apalutamide; Bicalutamide; Biospecimen Collection; Bone Scan; Buserelin; Computed Tomography; Degarelix; Flutamide; Goserelin; Histrelin; Leuprolide; Magnetic Resonance Elastography; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Radiation Therapy; Relugolix; Triptorelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-01-21
    Completion
    2038-12-31
    Enrolment
    2,753

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
    InterventionApalutamide; Bicalutamide; Biospecimen Collection; Bone Scan +14 more
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

    NCT03809000 · start 2019-04-15

    Registered record
    Registry ID
    NCT03809000
    Conditions
    Prostate Cancer
    Interventions
    Radiation Therapy; Enzalutamide; Bicalutamide; GnRH analog
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-04-15
    Completion
    2029-09-15
    Enrolment
    188

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionRadiation Therapy; Enzalutamide; Bicalutamide; GnRH analog
    PhasePhase 2
    Registry statusActive not recruiting

  • Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

    NCT03839823 · start 2019-02-25

    Registered record
    Registry ID
    NCT03839823
    Conditions
    Breast Cancer
    Interventions
    Docetaxel / Capecitabine; Capecitabine / Vinorelbine; Paclitaxel / Gemcitabine; Ribociclib; Letrozole OR Anastrozole; Goserelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-02-25
    Completion
    2023-05-10
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionDocetaxel / Capecitabine; Capecitabine / Vinorelbine; Paclitaxel / Gemcitabine; Ribociclib +2 more
    PhasePhase 2
    Registry statusCompleted

  • The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

    NCT03436745 · start 2019-01-22

    Registered record
    Registry ID
    NCT03436745
    Conditions
    Prostatic Neoplasms
    Interventions
    Zolpidem; ECG
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2019-01-22
    Completion
    2024-01-30
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms
    InterventionZolpidem; ECG
    PhasePhase 1
    Registry statusTerminated

  • Fulvestrant in Metastatic Breast Cancer

    NCT03591549 · start 2018-08-01

    Registered record
    Registry ID
    NCT03591549
    Conditions
    Metastatic Breast Cancer
    Interventions
    Faslodex; Zoladex
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-08-01
    Completion
    2021-10-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionFaslodex; Zoladex
    PhasePhase 4
    Registry statusUnknown

  • A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

    NCT03311555 · start 2018-03-28

    Registered record
    Registry ID
    NCT03311555
    Conditions
    Prostate Cancer
    Interventions
    Apalutamide; Androgen deprivation; Salvage radiation therapy; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-03-28
    Completion
    2022-12-22
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionApalutamide; Androgen deprivation; Salvage radiation therapy; Docetaxel
    PhasePhase 2
    Registry statusCompleted

  • A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer

    NCT03450109 · start 2017-12-22

    Registered record
    Registry ID
    NCT03450109
    Conditions
    Cancer of Prostate
    Interventions
    LY01005; Zoladex
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-12-22
    Completion
    2018-10-30
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer of Prostate
    InterventionLY01005; Zoladex
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual.

    NCT05304169 · start 2017-11-14

    Registered record
    Registry ID
    NCT05304169
    Conditions
    Prostate Cancer
    Interventions
    Leuprorelin Acetate (Eligard® 45 mg).
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-11-14
    Completion
    2020-06-15
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionLeuprorelin Acetate (Eligard® 45 mg).
    PhasePhase 4
    Registry statusCompleted

  • Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

    NCT03096847 · start 2016-10-24

    Registered record
    Registry ID
    NCT03096847
    Conditions
    Advanced Metastatic Breast Cancer
    Interventions
    ribociclib; letrozole; goserelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-10-24
    Completion
    2020-02-06
    Enrolment
    502

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Metastatic Breast Cancer
    Interventionribociclib; letrozole; goserelin
    PhasePhase 3
    Registry statusCompleted

  • Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer

    NCT02168062 · start 2014-06-16

    Registered record
    Registry ID
    NCT02168062
    Conditions
    Prostate Adenocarcinoma
    Interventions
    Behavioral Dietary Intervention; Counseling; Educational Intervention; Exercise Intervention; Goserelin Acetate; Laboratory Biomarker Analysis; Leuprolide Acetate; Quality-of-Life Assessment; Triptorelin Pamoate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-06-16
    Completion
    2018-05-22
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma
    InterventionBehavioral Dietary Intervention; Counseling; Educational Intervention; Exercise Intervention +5 more
    PhasePhase 2
    Registry statusTerminated

  • Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

    NCT01942135 · start 2013-09-26

    Registered record
    Registry ID
    NCT01942135
    Conditions
    Metastatic Breast Cancer
    Interventions
    Palbociclib; Fulvestrant; Placebo; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-09-26
    Completion
    2022-09-28
    Enrolment
    521

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionPalbociclib; Fulvestrant; Placebo; Fulvestrant
    PhasePhase 3
    Registry statusCompleted

  • Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate

    NCT02064036 · start 2013-06-06

    Registered record
    Registry ID
    NCT02064036
    Conditions
    Adenocarcinoma of the Prostate
    Interventions
    Stereotactic Radiosurgical Boost; Casodex; Leuprolide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-06-06
    Completion
    2021-10-29
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma of the Prostate
    InterventionStereotactic Radiosurgical Boost; Casodex; Leuprolide
    PhasePhase 1
    Registry statusCompleted

  • PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

    NCT01723774 · start 2013-04-10

    Registered record
    Registry ID
    NCT01723774
    Conditions
    Breast Neoplasms
    Interventions
    PD0332991; Anastrozole; Goserelin; Surgery (standard of care); Tumor biopsy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2013-04-10
    Completion
    2026-08-24
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms
    InterventionPD0332991; Anastrozole; Goserelin; Surgery (standard of care) +1 more
    PhasePhase 2
    Registry statusActive not recruiting